|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
WO2014080290A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Cyclic amines as bromodomain inhibitors
|
|
WO2014080291A2
(en)
|
2012-11-21 |
2014-05-30 |
Rvx Therapeutics Inc. |
Biaryl derivatives as bromodomain inhibitors
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
CA2903881C
(en)
|
2013-03-15 |
2021-05-18 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
EA027139B1
(ru)
*
|
2013-04-26 |
2017-06-30 |
Бейджин, Лтд. |
Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
|
|
MX365864B
(es)
|
2013-06-21 |
2019-06-18 |
Zenith Epigenetics Ltd |
Inhibidores de bromodominio biciclicos novedosos.
|
|
CA2915622C
(en)
|
2013-06-21 |
2020-08-18 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
EA201690087A1
(ru)
|
2013-07-31 |
2016-08-31 |
Зенит Эпидженетикс Корп. |
Новые квиназолиноны как ингибиторы бромодомена
|
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
WO2015164480A1
(en)
|
2014-04-23 |
2015-10-29 |
Incyte Corporation |
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
|
|
US9902702B2
(en)
*
|
2014-07-15 |
2018-02-27 |
Bristol-Myers Squibb Company |
Spirocycloheptanes as inhibitors of rock
|
|
US9527864B2
(en)
|
2014-09-15 |
2016-12-27 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
WO2016070037A2
(en)
|
2014-10-31 |
2016-05-06 |
Massachusetts Institute Of Technology |
Massively parallel combinatorial genetics for crispr
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
|
CN107207474B
(zh)
|
2014-12-11 |
2021-05-07 |
恒翼生物医药科技(上海)有限公司 |
被取代的杂环作为溴结构域抑制剂
|
|
JP2017538721A
(ja)
|
2014-12-17 |
2017-12-28 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメインの阻害剤
|
|
US10336697B2
(en)
|
2015-06-16 |
2019-07-02 |
Orion Corporation |
Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
TW201722966A
(zh)
|
2015-10-29 |
2017-07-01 |
英塞特公司 |
Bet蛋白質抑制劑之非晶固體形式
|
|
SMT202300155T1
(it)
|
2016-06-20 |
2023-07-20 |
Incyte Corp |
Forme solide cristalline di un inibitore di bet
|
|
WO2018109271A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
|
CN107739370B
(zh)
*
|
2017-10-26 |
2021-03-30 |
中国药科大学 |
吡咯酮类brd4蛋白抑制剂的制备方法以及用途
|
|
CN109928979B
(zh)
*
|
2017-12-15 |
2021-08-06 |
四川科伦博泰生物医药股份有限公司 |
吲哚酮类衍生物及其制备方法和用途
|
|
CN108383771A
(zh)
*
|
2018-01-08 |
2018-08-10 |
华东师范大学 |
手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
|
|
EP3843714B1
(en)
|
2018-08-27 |
2025-11-12 |
Arcus Biosciences, Inc. |
Cd73 inhibitors
|
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
US11078204B2
(en)
|
2018-11-13 |
2021-08-03 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
JP7636646B2
(ja)
|
2019-04-09 |
2025-02-27 |
オプナ バイオ ソシエテ アノニム |
Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
|
|
US20220378923A1
(en)
|
2019-09-30 |
2022-12-01 |
Kyowa Kirin Co., Ltd. |
Bet degrader
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
EP3912625A1
(en)
|
2020-05-20 |
2021-11-24 |
Kaerus Bioscience Limited |
Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
JP2025529185A
(ja)
*
|
2022-08-30 |
2025-09-04 |
パンネックス セラピューティクス インコーポレイテッド |
パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法
|
|
WO2025233532A1
(en)
|
2024-05-10 |
2025-11-13 |
Les Laboratoires Servier |
Maxi-k potassium channel openers and therapeutic applications thereof
|